

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

RECEIVED

NOV 02 2000

TECH CENTER 1601/2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/149,718
Filing Date	September 8, 1998
First Named Inventor	Games
Group Art Unit	1632
Examiner Name	Crouch, D.
Attorney Docket Number	ANS 101 CIP (2)

Sheet 1 of 16

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
dc		4,666,829		Glenner et al.	05-19-1987	
		4,736,866		Leder et al.	04-12-1998	
		4,873,191		Wagner et al.	10-10-1989	
		5,134,062		Blass	07-28-1992	
		5,200,339		Abraham	04-06-1993	
		5,234,814		Card et al.	08-10-1993	
		5,441,870		Seubert et al.	08-15-1995	
		5,547,841		Marotta et al.	08-20-1996	
dc		5,877,399		Hsiao et al.	03-02-1999	

## FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office. <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
dc		EP	0 123 527	B1	The Wistar Institute	01-17-1990		
a		EP	0 171 496	B1	Research Development Corporation of Japan	05-26-1993		
dc		EP	0 173 494	A2	The Board of Trustees of the Leland Stanford Junior University	03-05-1986		
dc		EP	0 184 187	A2	Teijin Limited	06-11-1986		
dc		EP	0 653 154	A2	Hoechst Japan Limited	05-17-1995		
dc		WO	86/01533		Celltech Limited	03-13-1986		

Examine Signature	Deborah Crouch	Date Considered	1/27/01
-------------------	----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

### Complete if Known

Application Number	09/149,718
Filing Date	September 8, 1998
First Named Inventor	Games
Group Art Unit	1632
Examiner Name	Crouch, D.
Attorney Docket Number	ANS 101 CIP (2)

Sheet 2 of 16

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office. <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
dc		WO	87/02671		International Genetic Engineering, Inc.	05-07-1987		
dc		WO	91/16628		The Regents of the University of California	10-31-1991		
dc		WO	92/00521		Case Western Reserve University	01-09-1992		
dc		WO	92/09699		L.F. Will & CIE S.A.	06-11-1992		
dc		WO	94/00569		Genpharm International	01-06-1994		
dc		WO	96/18900		Ramot-Univ. Authority for Applied Research and Industrial Development, Ltd.	06-20-1996		

### OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
dc		"Alzheimer's assault," <i>Science</i> 255(5048):1059 (1992).
dc		ABRAHAM, et al., "A calcium-activated protease from Alzheimer's disease brain cleaves at the N-terminus of the amyloid - protein," <i>Biochem. Biophys. Res. Comm.</i> 174:790-96 (1991).
dc		ALI, et al., "More transgenic mouse studies of Alzheimer amyloid precursor (AAP) proteins and derivatives," <i>Society for Neuroscience Abstracts</i> , 18:1445 (presentation 616.9) (1992).
dc		ALLISON, et al., "Diabetes in transgenic mice resulting from over-expression of class I histocompatibility molecules in pancreatic B cells," <i>Nature</i> (333)6173:529-33 (1988).

Examine Signature	Deborah Crouch	Date Considered	1/27/01
----------------------	----------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

OIP INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Use as many sheets as necessary)

Application Number

09/149,718

Filing Date

September 8, 1998

First Named Inventor

Games

Group Art Unit

1632

Examiner Name

Crouch, D.

Attorney Docket Number

ANS 101 CIP (2)

Sheet

3

of

16

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
de		ANTAL, et al., "Animal models of Alzheimer's, Parkinson's and Huntington's disease, A minireview," <i>Neurobiology (Bp)</i> 1(2):101-22 (1993).	
		BARTON, "Alteration in brain presenilin 1 mRNA expression in early onset familial Alzheimer's disease," <i>Neurodegeneration</i> 5:213-18 (1996).	
		BLASS, "Immunologic treatment of Alzheimer's disease," <i>The New England Journal of Medicine</i> 341(22):1694-95 (1999).	
		BREWER, "A G to C transversion in codon 258 of the -subunit of -hexosaminidase A in an infant Tay-Sachs disease patient," <i>Human Mutation</i> 2:496-97 (1993).	
		BRICE, et al., "Absence of the amyloid precursor protein gene mutation (APP717: Val->Ile) in 85 cases of early onset Alzheimer's disease," <i>J Neurol, Neurosurg, Psychiatry</i> 56(1):112-3 (1993).	
		CAIRNS, et al., "A4 protein deposition in familial Alzheimer's disease with the mutation in codon 717 Of the beta A4 amyloid precursor protein gene and sporadic Alzheimer's disease," <i>Neurosci Lett.</i> 149(2):137-40 (1993).	
		CARLSON, et al., "Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice," <i>Human Molecular Genetics</i> 6(11):1951-59 (1997).	
		CHAPMAN, et al., "Impaired synaptic plasticity and learning in aged amyloid precursor protein trasgenic mice," <i>Nature Neuroscience</i> 2(3):271-76 (1999).	
		CRAWFORD, et al., "Alzheimer's disease untangled," <i>BioEssays</i> (14)11:729 (1992).	
de		DAVIS, et al., "An Alzheimer's disease-linked PS1 variant rescus the developmental abnormalities of PS1-deficient embryos," <i>Neuron</i> 20:603-09 (1998).	

Examiner's  
Signature

Deborah Crouch

Date  
Considered

1/27/01


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	09/149,718
Filing Date	September 8, 1998
First Named Inventor	Games
Group Art Unit	1632
Examiner Name	Crouch, D.
Attorney Docket Number	ANS 101 CIP (2)

Sheet 4 of 16

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
de		DE STROOPER, et al., "Study of the synthesis and secretion of normal and artificial mutants of murine amyloid precursor protein (APP): cleavage of APP occurs in a late compartment of the default secretion pathway," <i>J Cell Biol.</i> 121(2):295-304 (1993).	
		DOVEY, et al., "Cells with a familial Alzheimer's disease mutation produce authentic Beta-peptide," <i>Neuroreport.</i> Aug;4(8):1039-42 (1993).	
		DUFF, "Alzheimer transgenic mouse models come of age," <i>TINS</i> 20(7):279-80 (1997).	
		DUFF, "Modeling Alzheimer's disease in transgenic mice," <i>J Florida M.A.</i> 91(9):625-28 (1994).	
		DUFF, "Recent work on Alzheimer's disease transgenics," <i>Curr Opin Biotech</i> 9:561-64 (1998).	
		DUFF, "Transgenic models for Alzheimer's disease," <i>Neuropathology and Applied Neurobiology</i> 24:101-03 (1998).	
		DUFF, et al., "Increased amyloid- 42(43) in brains of mice expressing mutant presenilin 1," <i>Nature</i> 383:710-13 (1996).	
		ERICKSON, "Model mice. Transgenic animals and Alzheimer's research," <i>Sci Am</i> 265(3):34 (1991).	
		FELSENSTEIN, et al., "Processing of the -amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <i>Neurosci Lett.</i> 152:185-89 (1993).	
de		FIDANI, et al., "Screening for mutations in the open reading frame and promoter of the -amyloid precursor protein gene in familial Alzheimer's disease: Identification of a further family with APP717 Val-->Ile," <i>Hum Mol Genet.</i> 1(3):165-68 (1992).	

Examiner's Signature	Deborah Crouch	Date Considered	1/27/01
----------------------	----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

O I P E  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Use as many sheets as necessary)

Application Number

09/149,718

Filing Date

September 8, 1998

First Named Inventor

Games

Group Art Unit

1632

Examiner Name

Crouch, D.

Attorney Docket Number

ANS 101 CIP (2)

Sheet

5

of

16

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
de		FISHER, et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <i>Proc Natl Acad Sci USA</i> 88(5):1779-82 (1991).	
		FORSS-PETTER, et al., "Transgenic mice expressing -galactosidase in mature neurons under neuron-specific enolase promoter control," <i>Neuron</i> 5(2):187-97 (1990).	
		FRANCIS, et al., "Animal and drug modelling for Alzheimer synaptic pathology," <i>Progress in Neurobiology</i> 39:517-45 (1992).	
		FRASER, et al., "Biochemistry and Alzheimer's disease amyloid plaques," <i>Clin Biochem</i> 46:339-49 (1993).	
		FRAUTSCHY, et al., "Microglial response to amyloid plaques in APPsw transgenic mice," <i>American Journal of Pathology</i> 152(1):307-17 (1998).	
		FUKUCHI, et al., "High levels of circulating -amyloid peptide do not cause cerebral -amyloidosis in transgenic mice," <i>American Journal of Pathology</i> 149(1):219-27 (1996).	
		FUKUCHI, et al., "Intestinal -amyloidosis; transgenic mice," <i>Society for Neuroscience Abstracts</i> 19:1035 (1993).	
		GALLAGHER, et al., "Animal models of normal aging: Relationship between cognitive decline and markers in hippocampal circuitry," <i>Behav Brain Res.</i> 57(2):155-62 (1993).	
		GANDY, et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <i>Trends Pharmacol Sci.</i> 13(3):108-13(1992).	
de		GLENNER, et al., "Alzheimer's disease and Down's Syndrome: Sharing of unique cerebrovascular amyloid fibril protein," <i>Biochem. Biophys. Res. Commun.</i> 122:1131-35 (1984).	

Examiner's  
Signature

Deborah Crouch

Date  
Considered

1/27/01


\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
 (use as many sheets as necessary)		Application Number	09/149,718
		Filing Date	September 8, 1998
		First Named Inventor	Games
		Group Art Unit	1632
		Examiner Name	Crouch, D.
		Attorney Docket Number	ANS 101 CIP (2)
Sheet	6	of	16

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
li		GODING, "Production and application of monoclonal antibodies in cell biology, biochemistry and immunology," in <i>Monoclonal Antibodies: Principles and Practice</i> , Ch. 3, pp. 56-74, (Academic Press, London 1984).	
		GOLDE, et al., "Production of amyloid protein from normal amyloid -protein precursor ( APP) and the mutated APPS linked to familial Alzheimer's disease," <i>Ann. N Y Acad. Sci.</i> , 695:103-08 (1993).	
		GOVERMAN, et al., "Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity," <i>Cell</i> 72:551-560 (1993).	
		GREAVES, et al., "A transgenic mouse model of sickle cell disorder," <i>Nature</i> (343):183-85 (1990).	
		GREENBERG, "Yet more transgenic mouse studies of Alzheimer amyloid precursor (APP)," <i>Society for Neuroscience Abstracts</i> 19:1035 (1993).	
		GREENBERG, et al., "Transgenic mouse studies for Alzheimer amyloid precursor (AAP) proteins and derivatives," <i>Society for Neuroscience Abstracts</i> , Vol 18:1445 (presentation 616.7) (1992).	
		HAASS, et al., "The Swedish mutation causes early-onset Alzheimer's disease by -secretase cleavage within the secretory pathway," <i>Nature Medicine</i> 1(12):1291-96 (1995).	
		HAASS, et al., "Amyloid -peptide is produced by cultured cells during normal metabolism," <i>Nature</i> 359:322-325 (1992).	
		HAMMER, et al., "Partial correction of murine hereditary growth disorder by germ-line incorporation of a new gene," <i>Nature</i> 311:65-67 (1984).	
li		HARDY, "New insights into the genetics of Alzheimer's disease," <i>Ann Med</i> 28(3):255-58 (1996).	

Examiner's Signature	Deborah Crouch	Date Considered	1/27/01
----------------------	----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Use as many sheets as necessary)

Application Number

09/149,718

Filing Date

September 8, 1998

First Named Inventor

Games

Group Art Unit

1632

Examiner Name

Crouch, D.

Attorney Docket Number

ANS 101 CIP (2)

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
dc		HARDY, "The Alzheimer family of diseases: many etiologies, one pathogenesis?," <i>Proc Natl Acad Sci USA</i> 94(6):2095-97 (1997).	
		HOEWSCH, et al., "The 5'-flanking region of the rat synapsin I gene directs neuron-specific and developmentally regulated reporter gene expression in transgenic mice," <i>J Biol Chem.</i> 268(35):26494-02 (1993).	
		HOLCOMB, et al., "Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant <i>amyloid precursor protein</i> and <i>presenilin 1</i> transgenes," <i>Nature Medicine</i> 4(1):97-100 (1998).	
		HOLTZMAN, et al., "Molecular studies in Alzheimer's disease," <i>Trends Biochem. Sci.</i> , 16(4):140-4 (1991).	
		HOWLAND, et al., "Modulation of secreted -amyloid precursor protein and amyloid -peptide in brain cholesterol," <i>J Biol Chem.</i> 273(26):16576-82 (1998).	
		HOWLAND, et al., "Neuron-specific expression of human amyloid precursor protein (APP) in transgenic mice," <i>Society for Neuroscience Abstracts</i> 19:1035 (1993).	
		HSIAO, "A proposed strategic research program for Alzheimer's disease," <i>Neurobiology of Aging</i> 15(2):S112-S115 (1994).	
		HSIAO, "From prion diseases to Alzheimer's disease," <i>J. Transm Suppl</i> 49:135-44 (1997).	
		HSIAO, "Strain dependent and invariant features of transgenic mice expressing Alzheimer amyloid precursor proteins," <i>Progress in Brain Research</i> 117:335-41 (1998).	
dc		HSIAO, "Transgenic mice expressing Alzheimer amyloid precursor proteins," <i>Experimental Gerontology</i> 33(718):883-89 (1998).	

Examiner's  
Signature

Deborah Crouch

Date  
Considered

1/27/01


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Use as many sheets as necessary) 		Application Number	09/149,718
		Filing Date	September 8, 1998
		First Named Inventor	Games
		Group Art Unit	1632
		Examiner Name	Crouch, D.
		Attorney Docket Number	ANS 101 CIP (2)
Sheet	8	of	16

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
dc		HSIAO, "Understanding the biology of -amyloid precursor proteins in transgenic mice," <i>Neurobiology of Aging</i> 16(4):705-06 (1995).	
		HSIAO, et al., "Molecular genetics and transgenic model of Gertsman-Straussler-Scheinker disease," <i>Alzheimer Dis Assoc Disord</i> 5(3):155-62 (1991).	
		HSIAO, et al., "Spontaneous neurodegeneration in transgenic mice with mutant prion protein," <i>Science</i> 250:1587-90 (1990).	
		HYMAN, et al., "Kunitz protease inhibitor-containing amyloid protein precursor immunoreactivity in Alzheimer's disease," <i>J. Neuropath. Exp. Neurol.</i> 51:76-83 (1992).	
		IADECOLA, et al., "SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein," <i>Nature Neuroscience</i> 2(2):157-161 (1999).	
		IRIZARRY, et al., "APP <sub>sw</sub> Transgenic mice develop age-related A deposits and neuropil abnormalities, but no neuronal loss in CA1," <i>J Neuropathol Exp Neurol.</i> 56(9):965-73 (1997).	
		IWAMOTO, et al., "Neuroblastoma in a transgenic mouse carrying a metallothionein/ret fusion gene," <i>Br J Cancer.</i> 67(3):504-47 (1993).	
		JAN & JAN, "Receptor-regulated ion channels," <i>Curr Opin Cell Biol</i> 9(2):155-60 (1997).	
		JOHNSTON-WOOD, et al., "Amyloid precursor protein processing and A 42 deposition in a transgenic mouse model of Alzheimer disease," <i>Proc Natl Acad Sci USA</i> 94(4):1550-55 (1997).	
dc		JONES, et al., "Mutation in codon 713 of the amyloid precursor protein gene presenting with Schizophrenia," <i>Genetics</i> , 1:306-309 (1992).	

Examiner's Signature	<i>Deborah A. Crouch</i>	Date Considered	1/27/01
----------------------	--------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

OCT 24 2000

## Complete if Known

Application Number

09/149,718

Filing Date

September 8, 1998

First Named Inventor

Games

Group Art Unit

1632

Examiner Name

Crouch, D.

Attorney Docket Number

ANS 101 CIP (2)

9

of

16

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
dc		JOYNER, et al., "Gene targeting: A practical approach," Oxford Press (1993).	
		KEFFER, et al., "Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis," <i>EMBO</i> 10(3):4025-31 (1991).	
		KENNEDY, et al., "Familial Alzheimer's disease. A pedigree with a mis-sense mutation in the amyloid precursor protein gene (amyloid precursor protein 717 Valine--> Glycine)," <i>Brain</i> 116 (pt 2):309-24 (1993).	
		KENNEDY, et al., "Only kunitz-inhibitor-containing isoforms of secreted Alzheimer amyloid precursor protein show amyloid immunoreactivity in normal cerebrospinal fluid," <i>Neurodegeneration</i> 1:59-64 (1992).	
		KOLIATSOS, et al., "Neurotrophic strategies for treating Alzheimer's disease: Lessons from basic neurobiology and animal models," <i>Ann. N Y Acad. Sci.</i> , 695:292-99 (1993).	
		KONIG, et al., "Identification and differential expression of a novel alternative splice isoform of the BA4 amyloid precursor protein (App) mRNA in leukocytes and brain microglial cells," <i>JBC</i> 267:10804-09 (1992).	
		KORF, et al., "S-antigen and rodopsin immunoreactions in midline brain neoplasms of transgenic mice: Similarities to pineal cell tumors and certain medulloblastomas in man," <i>J Neuropathol Exp Neurol</i> . 49(4):424-37 (1990).	
		KOZAK, "The scanning model for translation: An update," <i>J. Cell Biology</i> 108:229-41 (1989).	
		KOZLOWSKI et al., "The neurotoxic carboxy-terminal fragment of the Alzheimer amyloid precursor binds specifically to a neuronal cell surface molecule: Ph dependence of the neurotoxicity and the binding," <i>J. Neurosci.</i> , 12(5):1679-87 (1992).	
dc		KULJIS, et al., "Alzheimer-like diffuse amyloid plaques can be induced in transgenic mice expressing human 1-antichymotrypsin," <i>Soc. Neurosci. Abstr.</i> 9(2):1035 (1993).	

Examiner's Signature	Deborah Crouch	Date Considered	1/27/01
-------------------------	----------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
		Application Number	09/149,718
		Filing Date	September 8, 1998
		First Named Inventor	Games
		Group Art Unit	1632
		Examiner Name	Crouch, D.
Sheet 10 of 16	Attorney Docket Number	ANS 101 CIP (2)	

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
dc		KUMAR, "Mutations at codon 717 of the beta-amyloid precursor protein gene are a cause of Alzheimer's disease," <i>Indian J Exp Biol.</i> 30(2):156 (1992).	
		LAMB, et al., "Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice," <i>Human Molecular Genetics</i> 6(9):1535-41 (1997).	
		LAMB, et al., "Amyloid production and deposition in mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome transgenic mice," <i>Nature Neuroscience</i> 2(8):695-97 (1999).	
		LANNFELT, et al., "Low frequency of the APP 670/671 mutation in familial Alzheimer's disease in Sweden," <i>Neurosci Lett.</i> 153(1):85-7 (1993).	
		LAVIGUEUR, et al., "High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the P53 oncogene," <i>Molecular and Cellular Biology</i> 9(9):3982-91 (1989).	
		LENDON, et al., "Exploring the etiology of Alzheimer disease using molecular genetics," <i>Jama</i> 277(10):825-31 (1997).	
		LIEBERBURG, Abstract 421.15, "Expression of human Alzheimer's amyloid precursor protein in transgenic mice," <i>Society for Neuroscience Abstracts</i> 19:1035 (1993).	
		LUO, et al., "Human amyloid precursor protein ameliorates behavioral deficit of flies deleted for Appl Gene," <i>Neuron</i> 9(4):595-605 (1992).	
		MARX, "New lead to an Alzheimer's mouse?," <i>Science</i> 261(5128):1520 (1993).	
		MCPHEI, et al., "Neuronal expression of -amyloid precursor protein Alzheimer mutations causes intracellular accumulation of a C-terminal fragment containing both the amyloid and cytoplasmic domains," <i>J. Biol. Chem.</i> 272:24743-46 (1997).	

Examiner's Signature	<i>Deborah Crouch</i>	Date Considered	1/27/01
----------------------	-----------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary)

OCT 24 2000



## Complete if Known

Application Number 09/149,718  
Filing Date September 8, 1998  
First Named Inventor Games  
Group Art Unit 1632  
Examiner Name Crouch, D.  
Attorney Docket Number ANS 101 CIP (2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			T <sup>2</sup>
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
de		MILLER, et al., "Alzheimer's disease: Transgenic models to test new chemicals and pharmaceuticals," <i>Carr Opin Biotechnol</i> 6:683-686 (1992).	
		MUCKE, et al., "High-level neuronal expression of A in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation," <i>J. Neuroscience</i> 20(11):4050-58 (2000).	
		MULLAN, "Familial Alzheimer's disease: Second gene locus located," <i>BMJ</i> 305(6862):1108-9 (1992).	
		MULLAN, et al., "Genetic and molecular advances in Alzheimer's disease," <i>Trends Neurosci.</i> 16(10):398-403 (1993).	
		MULLINS, et al., "Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene," <i>Nature</i> 344:541-44 (1990).	
		MURAI, et al., "Twofold overexpression of human amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain surgery," <i>The Journal of Comparative Neurology</i> 392:428-38 (1998).	
		NEVE, et al., "Brain transplants of cells expressing the carboxyl-terminal fragment of the Alzheimer amyloid protein precursor cause specific neuropathology in vivo," <i>Proc. Natl. Acad. Sci. USA</i> 89(8):3448-52 (1992).	
		NGUYEN, et al., "The pathophysiological significance of nondesmodigleins targets of pemphigus autoimmunity," <i>Arch Dermatol.</i> 134:971-80 (1998).	
		NUSSBAUM, et al., "Alzheimer's disease and amyloid protein--in (transgenic) mice and man," <i>Harefuah</i> (Hebrew) 123(9):362-64 (1992).	
de		OLTERSDORF, et al., "The secreted form of the Alzheimer's amyloid precursor protein with the kunitz domain is protease nexin-II," <i>Nature</i> 341:144-47 (1989).	

Examiner's Signature

Deborah Chene

Date Considered


12/27/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
 (use as many sheets as necessary)		Application Number	09/149,718
		Filing Date	September 8, 1998
		First Named Inventor	Games
		Group Art Unit	1632
		Examiner Name	Crouch, D.
Sheet 12 of 16	Attorney Docket Number	ANS 101 CIP (2)	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
de		PALMERT, et al., "Soluble derivatives of the B amyloid protein precursor of Alzheimer's disease are labeled by antisera to the B amyloid protein," <i>Biochem. Biophys. Res. Comm.</i> 165:182-88 (1989).	
		PALMERT, et al., "The -amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid," <i>Proc. Natl. Acad. Sci USA</i> 86:6338-42 (1989).	
		PAPPOLLA, et al., "Evidence of oxidative stress and <i>in vivo</i> neurotoxicity of -amyloid in transgenic mouse model of Alzheimer's disease," <i>Amer. J. Path.</i> 152(4):871-77 (1998).	
		PAVLIN, "Brain amyloid in Alzheimer's disease--A new experimental model," <i>Neurol Croat</i> 41(4):227-34 (1992).	
		PEARSON, et al., "Nicotine intake and Alzheimer's disease," <i>BMJ</i> 303:361 (1991).	
		PERRAUD, et al., "The promotor of the human Cystic Fibrosis transmembrane conductance regulator gene directing SV40 T antigen expression induces malignant proliferation of ependymal cells in transgenic mice," <i>Oncogene</i> 5:993-97 (1992).	
		PRICE, et al., "Alzheimer's disease-type brain abnormalities in animal models," <i>Prog Clin Biol Res.</i> 379:271-87 (1992).	
		PULLIAM, et al., "Use of aggregating brain cultures to study the replication of herpes simplex virus types 1 and 2 in central nervous system tissue," <i>J. Virol. Met.</i> 9:301-16 (1984).	
		REAUME, "Enhanced amyloidogenic processing of the -amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and 'humanized' A sequence," <i>J. Biol. Chem.</i> 271(38):23380-88 (1996).	
de		ROBAKIS, et al., "An alternative secretase cleavage produces soluble Alzheimer amyloid precursor protein containing a potentially amyloidogenic sequence," <i>Soc. Neurosci., Abstract No.</i> 15.5, (1993).	


Examiner's Signature	Deborah Crouch	Date Considered	1/27/01
----------------------	----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
 Use as many sheets as necessary)		Application Number	09/149,718
		Filing Date	September 8, 1998
		First Named Inventor	Games
		Group Art Unit	1632
		Examiner Name	Crouch, D.
		Attorney Docket Number	ANS 101 CIP (2)
Sheet	13	of	16

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
dc		ROCH, et al., "Biologically active domain of the secreted form of the amyloid beta/A4 protein precursor," <i>Ann N Y Acad. Sci.</i> 695:149-57 (1993).	
		ROSSOR, et al., "Alzheimer's Disease families with amyloid precursor protein mutations," <i>Ann N Y Acad. Sci.</i> 695:198-202 (1993).	
		RYAN, et al., "Human sickle hemoglobin in transgenic mice," <i>Science</i> 247:566-68 (1990).	
		SAHASRABUDHE, et al., "Release of amino-terminal fragments from amyloid precursor protein reporter and mutated derivatives in cultured cells," <i>J. Biol. Chem.</i> , 267(35):25602-8 (1992).	
		SARVETNICK, et al., "Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma," <i>Cell</i> (52):773-82 (1988).	
		SAVAGE, et al., "Human amyloid precursor protein expression in transgenic mice as a model of Alzheimer's disease: A search for pathology," <i>Society for Neuroscience Abstracts</i> 19:1035 (1993).	
		SAVAGE, et al., "Turnover of amyloid -protein in mouse brain and acute reduction of its by phorbol ester," <i>Journal of Neuroscience</i> 18(5):1743-52 (1998).	
		SCHENK, et al., "The potential utility of transgenic mice harboring -amyloid precursor protein," <i>Neurobiology of Aging</i> 16(4):711-13 (1995).	
		SCHEUNER, et al., "Secreted amyloid -protein similar to that in the senile plaques of Alzheimer's disease is increased <i>in vivo</i> by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease," <i>Nature Medicine</i> 2(8):864-90 (1996).	
dc		SCOTT, et al., "Chimeric prion protein expression in cultured cells and transgenic mice," <i>Protein Science</i> 1:986-97 (1992).	


Examiner's Signature	Deborah Crouch	Date Considered	1/27/01
----------------------	----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
 Use as many sheets as necessary		Application Number	09/149,718
		Filing Date	September 8, 1998
		First Named Inventor	Games
		Group Art Unit	1632
		Examiner Name	Crouch, D.
Sheet	14	of	16
		Attorney Docket Number	ANS 101 CIP (2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			T <sup>2</sup>
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
de		SCOTT, et al., "Inability to detect beta-amyloid protein precursor mRNA in Alzheimer plaque-associated Microglia," <i>Exp. Neurol.</i> , 121(1):113-8 (1993).	
		SCOTT, et al., "The processing of native and mutant APP751 in human 293 cells," <i>Neurobiology of Aging Third International Conference on Alzheimer's Disease and Related Disorders</i> 13 (Suppl. 1):310 (1992).	
		SCOTT, et al., "Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques," <i>Cell</i> 59:847-857 (1989).	
		SELKOE, "Alzheimer's disease: Genotypes, phenotype, and treatments," <i>Science</i> 275(5300):630-31 (1997).	
		SELKOE, "The molecule pathology of Alzheimer's disease," <i>Neurom.</i> 6(4):487-98 (1991).	
		SELKOE, et al., "Amyloid precursor protein of Alzheimer disease occurs as 110-to 135-kilodalton membrane-associated proteins in neural and nonneural tissues," <i>Proc. Nat. Acad. Sci. USA</i> 85:7341-45 (1988).	
		SHIOSAKA, "Attempts to make models for Alzheimer's disease," <i>Neurosci Res</i> 13(4):237-55 (1992).	
		SIMAN, et al., "Processing of the beta-amyloid precursor. Multiple proteases generate and degrade potentially amyloidogenic fragments," <i>J. Biol. Chem.</i> , 268(22):16602-9 (1993).	
		SISODIA, "Amyloid precursor protein cleavage by a membrane-bound protease," <i>Proc Natl Acad Sci USA</i> 89(13):6075-79 (1992).	
de		SISODIA, et al., "Amyloidogenesis in Alzheimer's disease: Basic biology and animal models," <i>Curr Opin Neurobiol</i> 2(5):648-52 (1992).	
Examiner's Signature	Deborah Crouch		Date Considered
			11/27/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number

09/149,718

Filing Date

September 8, 1998

First Named Inventor

Games

Group Art Unit

1632

Examiner Name

Crouch, D.

Attorney Docket Number

ANS 101 CIP (2)

Sheet

15

of

16

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
de		SMITH, et al., "Amyloid- deposition in Alzheimer transgenic mice is associated with oxidative stress," <i>Journal of Neurochemistry</i> 70(5):2212-15 (1998).	
		SOFRONIEW, et al., "Transgenic modeling of neurodegenerative events gathers momentum," <i>Trends Neurosci.</i> 14(12):513-14 (1991).	
		STACEY, et al., "Perinatal lethal osteogenesis imperfecta in transgenic mice bearing an engineered mutant Pro-X1(I) collagen gene," <i>Nature</i> 332:131-36 (1988).	
		STOUT, et al., "Expression of human HPRT in the central nervous system of transgenic mice," <i>Nature</i> 317:250-52 (1985).	
		STURCHLER-PIERRAT, et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <i>Proc. Natl. Acad. Sci.</i> 94:13287-92 (1997).	
		THINAKARAN, et al., "Endoproteolysis of presenilin 1 and accumulation of processed derivatives <i>in vivo</i> ," <i>Neuron</i> 17:181-90 (1996).	
		TOMITA, et al., "The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue," <i>Proc Natl Acad Sci USA</i> 94(5):2025-30 (1997).	
		TRAVIS, "New piece in Alzheimer's puzzle," <i>Science</i> 261(5123):828-9 (1993).	
		TRUDEL, et al., "c-myc as an inducer of polycystic kidney disease in transgenic mice," <i>Kidney International</i> 39:665-71 (1991).	
de		USAMI, et al., "The triplet of lysine residues (Lys724-Lys725-Lys726) of Alzheimer's amyloid precursor protein plays an important role in membrane anchorage and processing," <i>J Neurochem.</i> 61(1):239-46 (1993).	

Examiner's  
Signature

Deborah Crouch

Date  
Considered


1/27/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) 		Application Number	09/149,718
		Filing Date	September 8, 1998
		First Named Inventor	Games
		Group Art Unit	1632
		Examiner Name	Crouch, D.
		Attorney Docket Number	ANS 101 CIP (2)
Sheet	of	16	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
de		VAN DUIJN, et al., "Genetic transmission of Alzheimer's disease among families in a dutch population based study," <i>J Med Genet.</i> 30(8):640-46 (1993).	
		VIDAL, et al., "Sequencing of the Alzheimer's APP gene dutch variant (APP-D)," <i>Hum Mutat.</i> 2(6):496-67 (1993).	
		WANG, et al., "Tissue and development-specific expression of the human phenylalanine hydroxylase/chloramphenicol acetyltransferase fusion gene in transgenic mice," <i>The Journal of Biological Chemistry</i> 267:15105-10 (1992).	
		WELLS, et al., "Human dystrophin expression corrects the myopathic phenotype in transgenic Mdx mice," <i>Human Molecular Genetics</i> 1(1):35-40 (1992).	
		WESTPHAL, "Mouse models of human diseases," <i>Curr Opin Biotechnol.</i> 2(6):830-3 (1991).	
de		ZHANG, et al., "Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein," <i>Journal of Neuroscience</i> 17(20):7655-61 (1997).	

Examiner's Signature	<i>Deborah Ann</i>	Date Considered	1/27/01
----------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.